MétaCan
Menu
← Back to cohort
Record W4407748997 · doi:10.1161/jaha.124.037899

In‐Hospital or Out‐of‐Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE‐HF Trial

2025· article· en· W4407748997 on OpenAlexaff
Nina Nouhravesh, Derek D. Cyr, Adrian F. Hernandez, David A. Morrow, Eric J. Velazquez, Jonathan H. Ward, Samiha Sarwat, Kavita Sharma, Kristin Williamson, Randall C. Starling, Serge Lepage, Shelley Zieroth, Scott D. Solomon, Robert J. Mentz

Bibliographic record

VenueJournal of the American Heart Association · 2025
Typearticle
Languageen
FieldMedicine
TopicHeart Failure Treatment and Management
Canadian institutionsUniversity of ManitobaUniversité de Sherbrooke
Fundersnot available
KeywordsMedicineEjection fractionValsartanSacubitrilHeart failureTolerabilitySacubitril, ValsartanCardiologyInternal medicineNatriuretic peptideHyperkalemiaRenal functionClinical endpointRandomized controlled trialAdverse effectBlood pressure

Abstract

fetched live from OpenAlex

Background Efficacy and tolerability of sacubitril/valsartan (Sac/Val) is not well characterized in heart failure (HF) with ejection fraction >40% initiated in‐hospital. Thus, this prespecified PARAGLIDE‐HF (Prospective Comparison of ARNI With ARB Given Following Stabilization In Decompensated HFpEF) analysis assessed the effects of Sac/Val versus valsartan (Val) by location of initiation in HF with ejection fraction >40% and recent worsening HF. Methods and Results This analysis of the double‐blind, randomized controlled trial assessed patients by in‐hospital and out‐of‐hospital (≤30 days of worsening HF) initiation. The primary end point was time‐averaged proportional change in NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) from baseline through weeks 4 and 8. A secondary hierarchical outcome consisted of cardiovascular death, HF hospitalizations, urgent HF visits, and NT‐proBNP change. Safety end points were symptomatic hypotension, hyperkalemia, and worsening renal function. Overall, 324 (70%, 162 Sac/Val, 162 Val) were initiated in‐hospital and 142 (71 Sac/Val, 71 Val) out‐of‐hospital. There was no evidence of a statistically significant differential treatment benefit of Sac/Val versus Val on NT‐proBNP change by location of initiation (in‐hospital, 0.86 [95% CI, 0.70–1.05] and out‐of‐hospital, 0.87 [95% CI, 0.70–1.09]; P interaction =0.99). The win ratio for the hierarchical outcome was 1.09 (95% CI, 0.82–1.45; P =0.57) for in‐hospital and 1.43 (95% CI, 0.91–2.26; P =0.12) for out‐of‐hospital. For the safety end points of symptomatic hypotension, hyperkalemia, and worsening renal function, no statistically significant differences in tolerability were seen between in‐hospital and out‐hospital initiation ( P interaction >0.1). Conclusions Sac/Val provided consistent benefit compared with Val, whether initiated in‐hospital or out‐of‐hospital in HF with ejection fraction >40% with a recent worsening HF event, demonstrating an opportunity to improve postdischarge outcomes by initiating Sac/Val during hospitalization.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.294
Teacher spread0.283 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Heart Association→Same topicHeart Failure Treatment and Management→French-language works237,207→